Polycystic ovary syndrome, or PCOS, is one of the most common endocrine disorders affecting women of reproductive age, characterized by irregular or absent ovulation, elevated androgen levels, and polycystic ovarian morphology on ultrasound. Because anovulation is the primary barrier to conception for many of these patients, the first-line treatment is typically oral medication that nudges the ovary to release an egg. Letrozole, an aromatase inhibitor originally developed for breast cancer, and clomiphene citrate, a selective estrogen receptor modulator used for decades, are the two workhorses of this approach. When ovulation is successfully induced, couples are advised to time intercourse to the fertile window, avoiding the cost and complexity of intrauterine insemination or in vitro fertilization, at least initially.

What has been missing from clinical guidance is a well-defined stopping point. International guidelines recommend ovulation induction as first-line therapy for anovulatory PCOS, but they offer limited evidence on how many cycles a patient should complete before the therapy is deemed exhausted. Continuing too long exposes women to repeated monitoring, medication, and emotional strain with diminishing returns; stopping too early may abandon a therapy that would eventually have worked. The Chinese team, led by Yuanlin Ma and corresponding author Qingyun Mai, set out to quantify that inflection point using cumulative live birth rate, the metric that fertility specialists regard as the most meaningful measure of treatment success because it counts the outcome patients actually care about: taking home a baby.

The study was designed as a prospective cohort investigation conducted between August 1, 2020, and June 30, 2023. Crucially, the researchers restricted enrollment to women whose ovaries had already demonstrated sensitivity to letrozole or clomiphene citrate, confirmed through hospital-based monitoring during the first treatment cycle. This design choice matters scientifically: rather than asking whether the drugs work in general, the investigators isolated the question of how many cycles a confirmed responder should continue. After that first monitored cycle, subsequent cycles were managed with home ovulation monitoring, a pragmatic real-world approach that reflects how most patients actually experience treatment outside of specialized research protocols.

The headline numbers tell a story of steady but finite returns. Of the 655 women enrolled, 306 achieved 372 pregnancies, of which 257 progressed to clinical pregnancy and 206 ended in live birth. Expressed as cumulative rates over the whole cohort, 46.72 percent of women achieved pregnancy, 39.24 percent achieved a clinical pregnancy, and 31.45 percent delivered at least one live baby. When the researchers plotted cumulative live birth rate against cycle number, the curve climbed briskly through the early cycles and then flattened decisively after the eighth cycle. In other words, the vast majority of the eventual success was captured within roughly a year and a half of attempted cycles, and cycles nine and beyond contributed almost nothing to the total.

The technical logic behind a cumulative live birth curve is worth unpacking, because it explains why this kind of analysis is so useful. Each cycle carries a per-cycle probability of success, and the cumulative rate aggregates those probabilities across successive attempts, accounting for the fact that women who conceive early drop out of the denominator of those still trying. A plateau in the cumulative curve signals that the residual per-cycle success rate among women still attempting has fallen so low that further cycles barely move the total. This is the same statistical framework used to counsel patients about in vitro fertilization, where cumulative live birth curves typically plateau after a certain number of egg retrieval attempts. Applying it to oral ovulation induction gives clinicians an evidence-based benchmark for a therapy that has long been guided by convention rather than data.

Two secondary findings from the study may prove just as consequential as the headline plateau. First, the researchers found that weight reduction was associated with a substantial boost in the maximal cumulative live birth rate, lifting it from 28.00 percent in the cohort overall to 39.02 percent among patients who lost weight. This aligns with a deep body of evidence that even modest weight loss in overweight women with PCOS can restore ovulatory function, improve insulin sensitivity, and enhance endometrial receptivity. The finding underscores that lifestyle intervention is not merely an adjunct to pharmaceutical treatment but can meaningfully amplify its yield, potentially changing the calculus of how many cycles are worth pursuing.

Second, metformin use was associated with reaching the cumulative live birth plateau earlier. Metformin, an insulin-sensitizing agent widely prescribed in PCOS, is thought to improve ovulatory function by addressing the hyperinsulinemia that drives many of the syndrome’s reproductive disturbances. If patients on metformin achieve their maximal cumulative benefit in fewer cycles, that has practical implications for treatment planning: it suggests the drug may accelerate the path to success among responders, allowing couples to reach either a live birth or a decision to escalate to assisted reproduction sooner. The researchers also stratified their analyses by PCOS phenotype, comparing patients with the classic hyperandrogenic presentation against those with ovulatory dysfunction and polycystic morphology without elevated androgens, acknowledging that PCOS is not a single entity but a spectrum.

The study’s strengths lie in its size, its prospective design, and its focus on a well-defined, clinically relevant population of drug-sensitive patients, all tracked through more than two and a half thousand monitored cycles. Its limitations are those inherent to a single-center observational cohort: the findings may not generalize to women who do not respond to first-line oral agents, to centers with different monitoring practices, or to populations with different baseline characteristics. The authors also note that the analysis was conducted on an intention-to-treat basis, which preserves real-world validity but cannot fully disentangle why some women discontinued treatment early. As with any cohort study, the associations with weight loss and metformin reflect patterns in the data rather than the results of randomized manipulation.

Even with those caveats, the practical message is strikingly clear for patients and clinicians navigating the early stages of fertility care. For women with PCOS who ovulate on letrozole or clomiphene citrate, eight cycles of ovulation induction with timed intercourse appear sufficient to capture the maximal cumulative live birth rate that this therapy can deliver, with weight loss and metformin offering avenues to improve the odds within that window. Couples who have not achieved a live birth by that point now have data-driven grounds to discuss escalation to intrauterine insemination or in vitro fertilization rather than continuing indefinitely down the same path. In a field where treatment decisions have often rested on tradition and intuition, a concrete, quantified stopping rule is a rare and welcome piece of clarity, and one that could spare countless patients months of futile cycles and the emotional toll that accompanies them.

Subject of Research: Optimal number of ovulation induction cycles with timed intercourse in letrozole- or clomiphene citrate-sensitive polycystic ovary syndrome

Article Title: When to stop? assessing the appropriate cycle of ovulation induction with timed intercourse in letrozole- or clomiphene citrate-sensitive polycystic ovary syndrome

Article References: Ma, Y., Liang, Q., Wen, T., Wang, C., Hu, R., Jie, H., Xu, Y., & Mai, Q. (2026). When to stop? assessing the appropriate cycle of ovulation induction with timed intercourse in letrozole- or clomiphene citrate-sensitive polycystic ovary syndrome. Journal of Ovarian Research. https://doi.org/10.1186/s13048-026-02283-8

Image Credits: AI Generated

DOI: 10.1186/s13048-026-02283-8

Keywords: polycystic ovary syndrome, ovulation induction, letrozole, clomiphene citrate, cumulative live birth rate, timed intercourse, fertility treatment, metformin, weight loss, infertility, reproductive medicine, anovulation

Intrauterine insemination is one of the most widely used forms of assisted reproductive technology. The procedure involves preparing a semen sample in the laboratory and then depositing the washed sperm directly into the uterine cavity around the time of ovulation, bypassing the cervix and shortening the distance sperm must travel to reach the egg. Compared with in vitro fertilization and embryo transfer, IUI is less invasive and less expensive, which makes it a common first-line treatment for couples with unexplained infertility, mild male factor infertility, or cervical factors, as well as for women with conditions such as polycystic ovarian syndrome. Yet despite its relative simplicity, the treatment cycle is psychologically intense. Patients face uncertainty about whether the cycle will succeed, repeated clinic visits timed to ovulation, hormonal monitoring, and the emotional whiplash of hope and disappointment that accompanies each attempt. Infertility itself is recognized by the World Health Organization as a medical condition, and a substantial body of literature has documented elevated anxiety, depression, and perceived stress among people navigating fertility care.

The Suzhou team enrolled participants from the hospital’s reproductive center and asked each woman to complete a battery of validated psychometric instruments. The General Information Questionnaire captured demographic and socioeconomic characteristics, including educational level and monthly household income. The Fertility Problem Inventory, commonly abbreviated FPI, measured infertility-related stress across multiple domains, producing a global stress score along with subscale scores reflecting concerns about social relationships, sexual relationships, the need for parenthood, the rejection of a child-free lifestyle, and the perceived importance of having children. The Stress Response Questionnaire, or SRQ, assessed the intensity of the women’s physiological and psychological reactions to stress, while the Coping Style Questionnaire, or CSQ, distinguished between positive coping strategies, such as active problem-solving and seeking social support, and negative coping strategies, such as avoidance and resignation. Follow-up sessions then recorded pregnancy outcomes, including clinical pregnancy and live birth rates, allowing the researchers to connect psychological profiles with reproductive results.

The headline finding was that these women reported substantial stress. The average global stress score on the Fertility Problem Inventory was 135.1, with a standard deviation of 18.2. To appreciate that number, it helps to understand how the FPI is constructed: higher scores reflect greater perceived stress related to the fertility problem, and a mean in the mid-130s indicates a clinically meaningful psychological burden across the group as a whole. The researchers then used general linear regression to evaluate which participant characteristics were associated with higher FPI scores. Three factors emerged as statistically significant: the outbreak of COVID-19, educational level, and monthly household income, each with P values below 0.05. In other words, women whose treatment intersected with the pandemic period, and women whose educational or economic circumstances differed, did not experience infertility-related stress equally.

The pandemic’s role deserves particular attention. Fertility care is uniquely vulnerable to public health disruptions. Treatment cycles require precise timing, frequent hospital visits, and laboratory procedures that cannot be postponed without losing the cycle entirely. During the COVID-19 outbreak, many reproductive centers faced restrictions, closures, or reduced capacity, and patients faced additional fears of infection, quarantine requirements, and uncertainty about whether their next appointment would proceed. The study’s finding that the COVID-19 outbreak significantly influenced infertility-related stress is consistent with the broader understanding that pandemic-era disruptions compounded the anxiety inherent in fertility treatment. For women already coping with the emotional weight of infertility, the pandemic added a second, independent layer of stress to an experience that was already among the most psychologically demanding in medicine.

Beyond the demographic and pandemic-related factors, the researchers examined how stress responses and coping styles related to the level of infertility-specific stress. Using Pearson correlation coefficients, they found that stress reactions measured by the SRQ were positively correlated with FPI scores, and that negative coping styles measured by the CSQ were also positively correlated with higher infertility-related stress, both with P values below 0.001. This pattern is psychologically coherent. Women who reacted to stressors with stronger physiological and emotional responses reported more infertility-related stress, and women who relied on maladaptive strategies such as avoidance reported more stress as well. The correlation does not establish causation in either direction; it is possible that high stress amplifies stress reactions, that reactive temperament magnifies perceived stress, or that both are driven by shared underlying factors. What the data do establish is that these psychological variables travel together, and that coping style is a meaningful correlate of how much distress a woman experiences during treatment.

The second major question the study addressed was whether this psychological burden translated into reproductive outcomes. Using logistic regression, the team analyzed the relationship between coping styles, perceived stress, the various FPI domains, and pregnancy outcomes. The result was, in one sense, reassuring: no statistically significant relationship was found between these psychological measures and clinical pregnancy or live birth. Women with higher stress scores and more negative coping styles were not, in this cohort, less likely to achieve a clinical pregnancy or deliver a live-born infant than women with lower stress and more adaptive coping. This finding aligns with a long-running and often contentious debate in reproductive medicine about whether psychological stress causes infertility treatment failure. While popular narratives frequently advise patients to simply relax in order to conceive, rigorous studies have repeatedly struggled to demonstrate a robust, independent effect of stress on treatment success, and the present results add to that skeptical literature.

The absence of an effect on outcomes should not be mistaken for evidence that the stress does not matter. The authors emphasize that women undergoing IUI exhibit significant levels of infertility-related stress, influenced by the COVID-19 outbreak, educational level, and family income, and that perceived stress and negative coping styles contribute to this burden. Chronic psychological distress is associated with diminished quality of life, strained relationships, and reduced treatment adherence and persistence, all of which affect patient well-being even if they do not alter the biology of implantation. The findings underscore, in the authors’ words, the need for targeted psychological interventions to support the well-being of women undergoing IUI, particularly during public health crises when external stressors multiply. Counseling, cognitive behavioral approaches, mindfulness-based stress reduction, and screening for maladaptive coping are all plausible avenues for such support within fertility clinics.

Methodologically, the study has notable strengths. It used validated, widely deployed instruments rather than ad hoc measures, tracked participants prospectively through follow-up to capture actual pregnancy outcomes, and applied a coherent statistical strategy: general linear regression for the determinants of stress, Pearson correlations for the relationships among psychological scales, and logistic regression for the link between psychological variables and outcomes. The study received ethical approval from the Institutional Review Board at the Second Affiliated Hospital of Soochow University, was conducted in accordance with the Declaration of Helsinki, and obtained informed consent from all participants. It was funded in part by the National Natural Science Foundation of China and by institutional and municipal grants, and the authors declared no competing interests. The work is published open access, making the full data and analysis available to clinicians and researchers worldwide.

There are, of course, limits to how far the conclusions can be generalized. The cohort comprised 243 women at a single reproductive center in Suzhou, and the study period, from January 2019 to July 2021, reflects the specific circumstances of the pandemic’s early phase in China. Stress, coping, and access to fertility care vary across cultures, health systems, and phases of a crisis, and the correlational design cannot disentangle cause from effect among the psychological variables. Nevertheless, the study offers a rare, quantified window into the mental health of fertility patients during a global emergency, and it delivers a clear message to clinics: the pandemic did not merely complicate the logistics of assisted reproduction, it measurably deepened the psychological burden on the women undergoing it. As health systems prepare for future crises, integrating psychological screening and support into fertility care should be treated not as an optional extra but as an essential component of treatment, even when, as here, the stress itself does not determine whether a pregnancy succeeds.

Subject of Research: Psychosocial stress and coping styles among women undergoing intrauterine insemination during the COVID-19 pandemic

Article Title: Psychosocial stress in women undergoing intrauterine insemination in the COVID-19 pandemic

Article References: Wang, X., Wu, L., Zhou, L., Shen, S., & Lyu, F. (2026). Psychosocial stress in women undergoing intrauterine insemination in the COVID-19 pandemic. Discover Psychology. https://doi.org/10.1007/s44202-026-00887-1

Image Credits: AI Generated

DOI: 10.1007/s44202-026-00887-1

Keywords: infertility, intrauterine insemination, COVID-19, psychosocial stress, coping styles, assisted reproductive technology, Fertility Problem Inventory, pregnancy outcomes, mental health, fertility treatment, China, public health crisis

The drug at the center of the question is propofol, a short-acting agent that has become the workhorse of general anesthesia for oocyte retrieval worldwide. Propofol acts rapidly on the central nervous system by modulating GABA receptors, producing sedation within seconds and clearing quickly once the infusion stops, which makes it ideal for procedures lasting under an hour. But propofol is also lipophilic and biologically active, and laboratory studies have suggested it can cross the follicular barrier and appear in follicular fluid. Animal and in vitro experiments have raised the theoretical possibility that anesthetic exposure around the time of fertilization could perturb calcium signaling, spindle dynamics, or mitochondrial activity in the oocyte, processes that are critical in the hours and days that follow. Whether these laboratory signals translate into any meaningful effect on real human embryos has remained stubbornly unclear.

The research team, led by Xingwu Wu and colleagues, tackled the problem with a tool that only recently became standard in advanced embryology laboratories: time-lapse imaging, or TLI. Conventional embryo assessment relies on brief, discrete snapshots, with embryologists lifting embryos from their incubators once a day to grade them under a microscope. That approach misses nearly everything that matters, because the most informative events of early development, including pronuclear appearance, syngamy, and each successive cell division, unfold in the dark between observations. Time-lapse incubators solve this by photographing each embryo every few minutes without disturbing it, generating a continuous film of development. The resulting timeline of events, known as morphokinetics, gives researchers an exquisitely sensitive readout of embryonic health, and it is precisely the kind of instrument needed to detect subtle delays or disruptions that an anesthetic agent might cause.

Between April and July 2023, the team enrolled 210 infertile women undergoing IVF or intracytoplasmic sperm injection at their center. Of these, 101 received propofol-based general anesthesia during oocyte retrieval, while 109 underwent the procedure without general anesthesia and served as the control group. Because the study was retrospective, the investigators took care to verify that the two groups were comparable before drawing any conclusions, and indeed baseline characteristics and ovarian stimulation outcomes were similar across the board. The number of oocytes retrieved did not differ significantly, nor did the hormonal profiles, laboratory metrics, or stimulation parameters that might otherwise confound a comparison of embryo quality. This methodological grounding matters enormously in anesthesia research, where differences in patient populations can easily masquerade as drug effects.

The primary outcomes were the morphokinetic parameters captured by the time-lapse system, and here the study delivered its most important findings. The researchers tracked the timing of pronuclear appearance, the moment when the two parental genetic packages first become visible as distinct structures within the fertilized egg, as well as the timings of cleavage to the two-, three-, four-, five-, and eight-cell stages, denoted t2 through t8. They also measured the onset of compaction, the start of blastulation, the time to full blastocyst formation, and the timing of blastocyst expansion. Across every one of these landmarks, the embryos of women who had received propofol were statistically indistinguishable from those of women who had not. The developmental clocks of the two groups ticked in unison, hour by hour, from fertilization through the blastocyst stage.

Secondary outcomes told the same story at the level of the laboratory and the clinic. The rate of normal fertilization, defined by the appearance of two pronuclei, was comparable between groups, as was the cleavage rate, the proportion of day-three embryos judged to be of good quality, and the rate at which embryos progressed to blastocysts. When fresh embryos were transferred, clinical pregnancy rates, miscarriage rates, and live birth rates were all similar between the anesthesia and control groups. In other words, the chain of events that begins with an anesthetized egg retrieval and ends with a take-home baby showed no detectable weak links attributable to propofol. For a field in which patients scrutinize every decision for possible harm to their chances, this consistency across endpoints carries real weight.

The technical strength of the study lies in its use of continuous morphokinetic monitoring rather than static morphology grading alone. Static grading can only describe what an embryo looks like at a given moment, whereas morphokinetics reveals how it got there, including subtle timing anomalies such as direct cleavage from one cell to three, prolonged pronuclear fading, or abnormal synchrony between cell divisions, all of which have been associated with poorer implantation potential in prior literature. Had propofol exposure imposed even a modest developmental delay or increased the frequency of atypical cleavage patterns, a time-lapse platform of this kind would be well positioned to detect it. The absence of any such signal, across a battery of timed landmarks, therefore represents a genuinely rigorous form of negative evidence rather than a simple failure to observe gross abnormalities.

As with any retrospective cohort study, the findings come with caveats that the authors and independent readers alike should keep in view. Allocation to anesthesia was not randomized, so residual confounding by indication, meaning systematic differences between patients who chose or were assigned general anesthesia and those who did not, cannot be entirely excluded, even with comparable baseline characteristics. The single-center design, while ensuring uniform laboratory protocols and embryology practices, means the results reflect one institution’s patient population and clinical routines. The sample size of 210 participants, though adequate for detecting moderate differences in morphokinetic timing, may not have been powered to exclude very small effects on rare outcomes such as miscarriage. The authors also note that the study was approved by their institutional ethics committee with written informed consent from all participants, and it was funded by the Natural Science Foundation of Jiangxi Province.

Even with those limitations, the study lands at a consequential moment. Propofol remains the default anesthetic for oocyte retrieval in most fertility centers because it offers rapid onset, swift recovery, and reliable patient comfort during an uncomfortable transvaginal needle procedure, and alternatives such as conscious sedation or paracervical blocks each carry their own trade-offs in efficacy and tolerability. Persistent uncertainty about embryonic effects has left some patients and clinicians to weigh comfort against a feared, but unquantified, reproductive risk. By combining a clinically relevant exposure, a sensitive continuous imaging platform, and a full chain of outcomes from fertilization through live birth, the Nanchang team has provided the kind of reassuring, mechanistically informed data that the field has needed. The message for patients heading into an egg retrieval is straightforward: choosing general anesthesia with propofol to stay comfortable during the procedure does not appear to cost their embryos anything measurable, either in the incubator or in the clinic.

Subject of Research: Effects of propofol general anesthesia during oocyte retrieval on embryo morphokinetics and IVF clinical outcomes

Article Title: Effects of general anesthesia with propofol during oocyte retrieval on embryo morphokinetics and clinical outcomes: a retrospective cohort study

Article References: Wu, X., Zhong, Y., Xia, L., Huang, J., Chen, J., Zhang, Z., Liu, P., Tian, L., Tan, J., Chen, H., Xin, C., Huang, Z., & Zhao, Y. (2026). Effects of general anesthesia with propofol during oocyte retrieval on embryo morphokinetics and clinical outcomes: a retrospective cohort study. Journal of Ovarian Research. https://doi.org/10.1186/s13048-026-02289-2

Image Credits: AI Generated

DOI: 10.1186/s13048-026-02289-2

Keywords: propofol, general anesthesia, oocyte retrieval, IVF, ICSI, embryo morphokinetics, time-lapse imaging, blastocyst, clinical pregnancy, live birth, fertility treatment, retrospective cohort study

The study, published in the Journal of Ovarian Research, is notable less for introducing a new model than for testing one rigorously. Prediction models in reproductive medicine are abundant, but very few are subjected to what statisticians call external validation, the process of confirming that a tool works not just in the population where it was developed but in entirely new groups of patients treated at different hospitals. Without such validation, a model’s apparent accuracy may be nothing more than a statistical artifact of its original dataset, a phenomenon researchers describe as overfitting.

To address this, a team led by Chang Liu, Huan Zhang and Yili Teng of the Reproductive Medicine Center at the First Affiliated Hospital of Wenzhou Medical University assembled an exceptionally large cohort: 14,702 women aged 35 or younger undergoing their first IVF or ICSI cycle between January 2023 and December 2025. The data came from six reproductive centers across several Chinese provinces, including sites in Shandong, Zhejiang, Guangxi and elsewhere. The researchers validated the existing nomogram, a graphic scoring instrument that converts patient characteristics into a probability, using two complementary strategies. Temporal validation tested the model on later patients at the original development center, while geographic validation tested it across five independent hospitals.

All of the predictors in the model are collected before ovarian stimulation begins, which is precisely what makes the tool clinically actionable. They include the woman’s age, her anti-Müllerian hormone level, her antral follicle count as seen on ultrasound, her baseline follicle-stimulating hormone level, and the ratio of follicle-stimulating hormone to luteinizing hormone. Each of these measures reflects a different facet of what reproductive biologists call the ovarian reserve, the pool of remaining follicles in the ovaries. Anti-Müllerian hormone, secreted by small growing follicles, serves as a chemical census of that pool. The antral follicle count provides a direct visual count of recruitable follicles, while FSH and its ratio to LH capture how hard the pituitary gland must work to drive the ovaries, a signal that rises as ovarian responsiveness declines.

The scale of the problem the model addresses is underscored by the study’s headline finding: across all six centers, the rate of low oocyte retrieval among these young women reached 47.2 percent. In other words, nearly one in two patients who might assume that youth guarantees a bountiful egg harvest in fact ended their first stimulation cycle with a disappointing yield. Low oocyte retrieval matters because the number of eggs retrieved is tightly linked to the number of embryos available for transfer, the chances of success per cycle, and the emotional and financial burden placed on patients who must repeat stimulation or accumulate eggs over multiple attempts.

The validation results were strikingly consistent. Across the six centers, the model’s area under the receiver operating characteristic curve, a standard measure of discrimination that reflects how well a tool separates those who will experience an outcome from those who will not, ranged from 0.800 to 0.888, with an overall value of 0.836 and a 95 percent confidence interval of 0.829 to 0.842. In practical terms, an AUC above 0.8 is generally regarded as good discrimination, meaning that a randomly chosen patient who experiences low oocyte retrieval receives a higher risk score than a randomly chosen patient who does not roughly four times out of five. That level of performance, sustained across hospitals with different patient populations and laboratory practices, is the strongest evidence yet that the underlying biology captured by the five parameters is genuinely generalizable.

Discrimination alone, however, is not enough for a clinical tool. A model must also be well calibrated, meaning that when it predicts, for example, a 30 percent risk of low retrieval, roughly three in ten comparable patients actually experience it. The researchers assessed this using calibration plots and the mean absolute error, a metric that quantifies the average gap between predicted and observed probabilities. The mean absolute error values ranged from just 0.004 to 0.040 across centers, indicating that the nomogram’s predicted probabilities track observed outcomes closely. Such calibration is what allows clinicians to communicate a risk estimate to a patient and trust that the number carries real meaning rather than systematic distortion.

The team also evaluated clinical usefulness through decision curve analysis, a technique that weighs the benefits of correctly identifying high-risk patients against the costs of unnecessary interventions in low-risk ones. Compared with the extreme strategies of treating everyone or treating no one, the nomogram delivered a higher net benefit across a broad range of threshold probabilities, the risk levels at which a clinician and patient would choose to act. The researchers found no statistically significant association between center-level characteristics and model discrimination, though they noted that variation in AUC across sites may still reflect differences in patient characteristics, a reminder that even validated tools perform within the texture of local populations.

For patients and clinicians, the practical implications are considerable. A woman identified as high risk before stimulation could, in principle, be counseled more realistically about her first cycle, offered an individualized stimulation protocol with adjusted gonadotropin dosing, or prepared for the possibility of a dual-ovulation or multiple-cycle approach to accumulate eggs. Low oocyte retrieval in young patients can signal an occult diminished ovarian reserve or unexpected hyporesponsiveness that standard screening sometimes misses, and early identification turns a cycle-ending surprise into a manageable planning problem. Because every input to the nomogram is already part of routine pretreatment workup in IVF clinics worldwide, implementing the tool requires no new tests, only a calculation.

The study was approved by the institutional review board of the First Affiliated Hospital of Wenzhou Medical University and conducted in accordance with the Declaration of Helsinki, with informed consent waived given its retrospective design. Funded by the Wenzhou Municipal Science and Technology Bureau, the work arrives amid a broader movement in reproductive medicine toward pretreatment risk stratification, in which statistical and machine-learning models compress thousands of patient records into instruments usable at the bedside. This nomogram, now tested across six hospitals and nearly fifteen thousand patients, offers one of the clearest demonstrations that such tools can travel well beyond their birthplace. For the roughly half of young IVF patients who would otherwise be blindsided by a poor egg retrieval, that portability may prove the study’s most valuable result, turning a moment of disappointment into an opportunity for foresight.

Subject of Research: External validation of a pretreatment prediction nomogram for low oocyte retrieval in young women undergoing IVF/ICSI

Article Title: Prediction of low oocyte retrieval in young women undergoing IVF/ICSI: a multicenter external validation study

Article References: Liu, C., Zhang, H., Yang, H., Sun, Z., Zhu, Q., Zhang, S., Lv, Y., Fu, X., Dai, C., & Teng, Y. (2026). Prediction of low oocyte retrieval in young women undergoing IVF/ICSI: a multicenter external validation study. Journal of Ovarian Research. https://doi.org/10.1186/s13048-026-02266-9

Image Credits: AI Generated

DOI: 10.1186/s13048-026-02266-9

Keywords: IVF, ICSI, low oocyte retrieval, ovarian reserve, anti-Müllerian hormone, antral follicle count, nomogram, predictive model, multicenter validation, reproductive medicine, fertility treatment, ovarian stimulation